



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Kjell G.E. Bäckström et al.
Serial No. : 08/736,267
Filed : October 24, 1996
Title : COMPOSITIONS FOR INHALATION

Art Unit : 1653
Examiner : D. Lukton

Commissioner for Patents
Washington, D.C. 20231

RECEIVED
OCT 12 2001
TECH CENTER 1600/2300

TERMINAL DISCLAIMER UNDER 37 CFR §§3.73(b) AND 1.321(b)

Pursuant to 37 CFR §3.73(b), AstraZeneca AB, a corporation, certifies that it is the successor of Astra Aktiebolag, assignee of the entire right, title, and interest in the above application by virtue of an assignment from the inventors of the patent application identified above. The assignment was recorded in the Patent and Trademark Office for Astra Aktiebolag at Reel 7172, Frame 0512 on September 6, 1994. The Certificate of Registration indicating the name change from Astra Aktiebolag to AstraZeneca AB was recorded in the Patent and Trademark Office at Reel 011469, Frame 0958 on January 22, 2001.

In addition, pursuant to 37 CFR §3.73(b), AstraZeneca AB, a corporation, certifies that it is the successor of Astra Aktiebolag, assignee of the entire right, title, and interest in the co-pending patent application serial no. 08/960,093 by virtue of an assignment from the inventors thereof. This assignment was recorded in the Patent and Trademark Office for Astra Aktiebolag at Reel 7895, Frame 0951 on April 15, 1996.

The undersigned has reviewed all the documents in the chain of title of the above-identified application and to the best of undersigned's knowledge and belief, title is in AstraZeneca AB.

The undersigned is empowered to act on behalf of the AstraZeneca AB.

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

OCTOBER 4, 2001
Date of Deposit

Signature

KATHLEEN PHILPOT
Typed or Printed Name of Person Signing Certificate

10/11/2001 HABB11 00000064 08736267

02 FC:148

110.00 OP

Applicant : Kjell G.E. Backstrom et al.
Serial No. : 08/736,267
Filed : October 24, 1996
Page : 2

Attorney's Docket No.: 06275-004001 / D 1271-7 US

Pursuant to 37 CFR §1.321(b), and to obviate a double patenting rejection, AstraZeneca AB hereby waives and disclaims the terminal portion of the term of the entire patent to be granted upon application serial no. 08/736,267 subsequent to the expiration date of any patent that may issue on application serial no. 08/960,093. Further, any patent granted on application serial no. 08/736,267 shall be enforceable only for and during such period that said patent is commonly owned with any patent that may issue on application serial no. 08/960,093.

AstraZeneca AB does not disclaim any terminal part of any patent granted on application serial no. 08/736,267 prior to the expiration date of the full statutory term of any patent that may issue on application serial no. 08/960,093 in the event that the latter patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR §1.321, has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term, except for the separation of legal title as stated above.

This disclaimer runs with any patent granted on application serial no. 08/736,267 and is binding upon the grantee, its successors or assigns.

A check for the \$110 fee required by 37 CFR § 1.20 (d) is enclosed. Please charge any additional fees, or make any credits, to Deposit Account No. 06-1050, referencing Attorney Docket No. 06275-004001.

Respectfully submitted,

Date:

Oct. 4, 2001

Janis K. Fraser, Ph.D., J.D.
Reg. No. 34,819

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906